

*In re Andersen et al.*  
*Application No. 10/649,386*

*Page 2 of 6*  
*6150.210-US*

---

### **AMENDMENTS TO THE CLAIMS**

The following Listing of Claims replaces all prior versions, and listings, of claims.

### **LISTING OF CLAIMS**

1-8 (cancelled)

9. (new) A method of decreasing food intake in a subject comprising administering to the subject an effective amount of a growth hormone secretagogue receptor type 1A (GHS-R 1A) antagonist.

10. (new) The method of claim 9, wherein the subject is a household pet.

11. (new) The method of claim 9, wherein the subject is a human.

12. (new) The method of claim 11, wherein the GHS-R 1A antagonist is administered with one or more antiobesity agents or food intake-regulating agents.

13. (new) A method of treating Type II diabetes in a subject comprising administering to the subject an effective amount of a GHS-R 1A antagonist.

14. (new) The method of claim 13, wherein the subject is a household pet.

15. (new) The method of claim 13, wherein the subject is a human.

16. (new) The method of claim 15, wherein the GHS-R 1A antagonist is administered with an antidiabetic agent.

*In re Andersen et al.*  
*Application No. 10/649,386*

*Page 3 of 6*  
*6150.210-US*

---

17. (new) A method for treating obesity in a subject comprising administering to the subject an effective amount of a GHS-R 1A antagonist.
18. (new) The method of claim 17, wherein the subject is a household pet.
19. (new) The method of claim 17, wherein the subject is a human.
20. (new) The method of claim 19, wherein the GHS-R 1A antagonist is administered with one or more antiobesity agents or food intake-regulating agents.
21. (new) A method for decreasing body mass index (BMI) of a subject, comprising administering to a subject in need thereof a GHS-R 1A antagonist in an amount effective for decreasing BMI.
22. (new) The method of claim 21, wherein the subject is a household pet.
23. (new) The method of claim 21, wherein the subject is a human.
24. (new) The method of claim 23, wherein the GHS-R 1A antagonist is administered with one or more antiobesity agents or food intake-regulating agents.
25. (new) A pharmaceutically acceptable composition comprising as an active ingredient a GHS-R 1A antagonist and a pharmaceutically acceptable carrier or diluent.
26. (new) The composition of claim 25, wherein the antagonist is an antagonist for the human GHS-R 1A.

*In re Andersen et al.*  
*Application No. 10/649,386*

*Page 4 of 6*  
*6150.210-US*

---

27. (new) The composition of claim 26, wherein the composition is formulated for oral, rectal, nasal, transdermal, pulmonary, or parenteral administration.

28. (new) The composition of claim 27, wherein the composition further comprises as an active ingredient one or more antiobesity agents, food intake-regulating agents, or antidiabetic agents.